Company Quick10K Filing
BlackRidge Technology
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 97 $23
10-Q 2019-11-14 Quarter: 2019-09-30
10-Q 2019-08-14 Quarter: 2019-06-30
10-Q 2019-05-15 Quarter: 2019-03-31
10-K 2019-04-15 Annual: 2018-12-31
10-Q 2018-11-14 Quarter: 2018-09-30
10-Q 2018-08-14 Quarter: 2018-06-30
10-Q 2018-05-15 Quarter: 2018-03-31
10-K 2018-04-02 Annual: 2017-12-31
10-Q 2017-11-14 Quarter: 2017-09-30
10-Q 2017-08-14 Quarter: 2017-06-30
10-Q 2017-05-15 Quarter: 2017-03-31
10-K 2017-04-14 Annual: 2016-12-31
10-Q 2016-11-14 Quarter: 2016-09-30
10-Q 2016-08-15 Quarter: 2016-06-30
10-Q 2016-05-20 Quarter: 2016-03-31
10-K 2016-03-30 Annual: 2015-12-31
10-Q 2015-11-16 Quarter: 2015-09-30
10-Q 2015-08-14 Quarter: 2015-06-30
10-Q 2015-05-13 Quarter: 2015-03-31
10-K 2015-03-31 Annual: 2014-12-31
10-Q 2014-11-18 Quarter: 2014-09-30
10-Q 2014-08-14 Quarter: 2014-06-30
10-Q 2014-05-20 Quarter: 2014-03-31
10-K 2014-03-31 Annual: 2013-12-31
10-Q 2013-11-14 Quarter: 2013-09-30
10-Q 2013-08-14 Quarter: 2013-06-30
10-Q 2013-05-15 Quarter: 2013-03-31
10-K 2013-04-15 Annual: 2012-12-31
10-Q 2012-11-14 Quarter: 2012-09-30
10-Q 2012-08-14 Quarter: 2012-06-30
10-Q 2012-05-15 Quarter: 2012-03-31
10-K 2012-03-30 Annual: 2011-12-31
10-Q 2011-11-10 Quarter: 2011-09-30
10-Q 2011-08-12 Quarter: 2011-06-30
10-Q 2011-05-13 Quarter: 2011-03-31
10-K 2011-03-31 Annual: 2010-12-31
10-Q 2010-11-09 Quarter: 2010-09-30
10-Q 2010-08-13 Quarter: 2010-06-30
8-K 2019-05-29 Other Events, Exhibits
8-K 2019-01-08 Other Events, Exhibits
8-K 2018-08-23 Amend Bylaw, Shareholder Vote, Exhibits
8-K 2018-05-17 Officers, Other Events, Exhibits
8-K 2018-01-29 Accountant, Exhibits

BlackRidge Technology Financials

BRTI Metrics, Comps, Filings

Annual | Quarterly

Business

On September 6, 2016, BlackRidge Technology International, Inc. and BlackRidge Technology Holdings, Inc., a Delaware corporation (the "Company", or "BlackRidge"), entered into an Agreement and Plan of Reorganization (the "Reorganization Agreement") originally dated as of September 6, 2016 and amended on February 22, 2017 to update the number of common shares, warrants, and options granted and outstanding as of the closing date.

On February 22, 2017, we completed the actions contemplated by the Reorganization Agreement and merged with and into BlackRidge with BlackRidge continuing as the surviving corporation ("Reorganization"). Upon completion of the Agreement, we issued 3,783,791 shares of our newly designated Series A Preferred Stock and 12,825,683 shares of Common Stock to the stockholders of BlackRidge in exchange for all the issued and outstanding shares of Series A Preferred Stock and Common Stock of BlackRidge. Additionally, certain stockholders of the Company returned for cancellation a total of 16,284,330 shares of our Common Stock. Upon the completion of the Reorganization, BlackRidge became a wholly-owned subsidiary of the Company and the Company had a total of 3,783,791 shares of Series A Preferred Stock and 21,790,683 shares of Common Stock outstanding, with the former BlackRidge stockholders owning 3,783,791 shares or 100% of Series A Preferred Stock and 12,825,683 shares or approximately 58.9% of Common Stock. Upon completion of the Reorganization, we also had outstanding warrants entitling the holders to acquire a total of 18,541,579 shares of the Company's Common Stock at an average exercise price of $0.46 per share. The Reorganization resulted in a change of control of the Company. For accounting purposes, BlackRidge will be treated as the acquirer and the historical financial statements of BlackRidge will become the Company's historical financial statements. The acquisition is intended to constitute a tax-free reorganization pursuant to the applicable provisions of the Internal Revenue Code of 1986, as amended.

At the closing of the Reorganization, Robert Graham was appointed as President, and John Bluher was appointed Chief Financial Officer, Treasurer and Secretary. In addition, Bruce Crane resigned from his position as a director and Robert Graham was appointed as a director of the Company to fill the vacancy created by such resignation. John Hofman, our remaining director, resigned from such position effective following our compliance with rule 14f-1 promulgated under the Exchange Act, and John Hayes and Robert Lentz were appointed as directors of the Company effective at such time as Mr. Hofman's resignation became effective.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Biotricity (BTCY) 24,424 50% -3.2 -789% 1,047 4,312 708 357 -8,261 -8,261 26,560
Invesco DB G10 Currency Harvest Fund (DBV) 24,290 86.3 1% 24,330 20 0 0 280 281 24,267
Metaurus Equity Component Trust (XDIV) 24,128 7.5 13% 24,486 344 0 0 3,153 3,153 23,662
Nexien BioPharma (NTVA) 24,080 -5.6 -1,384% 311 45 0 0 -4,301 -4,301 23,933
Lifeloc Technologies (LCTC) 23,928 46% 25.1 4% 8,782 2,369 8,513 3,901 378 907 22,783
Sierra Monitor (SRMC) 23,849 78% 32.4 1% 11,778 2,813 17,068 13,240 160 666 21,593
Znergy (ZNRG) 23,572 14% -7.3 -336% 1,025 1,831 1,222 173 -3,443 -3,234 23,566
Draper Oakwood Technology Acquisition (DOTA) 23,547 -218.6 -0% 58,936 53,936 0 0 -160 -108 23,539
BioCardia (BCDA) 23,463 -7% -1.6 -538% 2,716 4,952 489 -33 -14,601 -14,508 22,946
BlackRidge Technology (BRTI) 23,351 95% -1.6 -242% 10,714 18,887 367 349 -25,888 -14,352 23,473
Barington/Hilco Acquisition (BHAC) 23,189 -6.7 -22% 9,481 4,481 0 0 -2,081 -2,081 13,844
Provectus Biopharmaceuticals (PVCT) 23,094 -3.6 -261% 2,718 23,684 0 0 -7,105 -6,028 21,770
Nukkleus (NUKK) 23,049 2% -46.5 -136% 324 1,307 19,200 300 -439 -495 23,040
Astro Aerospace (ASDN) 23,044 -3.0 850,352,200% 0 0 -8,504 -7,751 23,019
Trident Brands (TDNT) 22,618 27% -2.9 -186% 5,394 24,698 2,613 696 -10,055 -7,166 20,964
Cincinnati Bancorp (CNNB) 22,616 2.3 1% 206,334 182,814 0 0 2,248 5,006 11,468
Axovant Sciences (AXON) 22,553 0.2 -104% 101,445 72,093 0 0 -105,234 -96,181 -21,373
Synergy CHC (SNYR) 22,472 63% -22.7 -20% 17,493 11,759 30,201 19,133 -3,536 -1,237 28,038
Hedgepath Pharmaceuticals (HPPI) 22,227 -5.2 -184% 2,132 3,305 0 0 -3,917 -3,917 20,202

Balance Sheet ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash251238796191124224,694
Accounts Receivable508054583938217102
Inventory1191512893287091,0624056
PP&E71571721571401218879
Assets7689618961,0571,0251,4468,17313,974
Accounts Payable31
Long-Term Debt1441453670
Liabilities3634484025465659256,6048,806
Stockholders' Equity4055124945124595201,5685,168
Income Statement ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue1,6811,88262681,4461,00682248
Cost of Revenue1,2021,3181,1119471,1117451117
Gross Profit48056441140841626271231
R&D
SG&A40139241041030432013,01914,059
Tax15437200000
Net Income42107-18-43-52-259-15,346-17,151
Cash Flow ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating126155-150-223-30-244-7,702-10,653
Cash Investing-156-5-14-1,517-2,309
Cash Financing13-13-3206-213439,59317,234